WO1998052603A3 - Vaccin comprenant de l'adn a enveloppe du virus de la grippe - Google Patents

Vaccin comprenant de l'adn a enveloppe du virus de la grippe Download PDF

Info

Publication number
WO1998052603A3
WO1998052603A3 PCT/EP1998/003050 EP9803050W WO9852603A3 WO 1998052603 A3 WO1998052603 A3 WO 1998052603A3 EP 9803050 W EP9803050 W EP 9803050W WO 9852603 A3 WO9852603 A3 WO 9852603A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
mumps virus
virosomes
virus
biologically active
Prior art date
Application number
PCT/EP1998/003050
Other languages
English (en)
Other versions
WO1998052603A2 (fr
Inventor
Maria Grazia Cusi
Reinhard Glueck
Ernst WAELTI
Original Assignee
Schweiz Serum & Impfinst
Maria Grazia Cusi
Reinhard Glueck
Ernst WAELTI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst, Maria Grazia Cusi, Reinhard Glueck, Ernst WAELTI filed Critical Schweiz Serum & Impfinst
Priority to AU79153/98A priority Critical patent/AU7915398A/en
Priority to EP98929369A priority patent/EP0988052A2/fr
Publication of WO1998052603A2 publication Critical patent/WO1998052603A2/fr
Publication of WO1998052603A3 publication Critical patent/WO1998052603A3/fr
Priority to US10/269,501 priority patent/US20030113347A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne des virosomes comprenant des lipides cationiques, de la protéine d'hémagglutinine de la grippe biologiquement active, ou des dérivés biologiquement actifs de ces derniers, et des acides nucléiques codant des antigènes à partir de sources pathogènes dans leurs intérieurs, de préférence, des antigènes provenant du virus des oreillons. Ces antigènes sont dérivés de protéines externes et internes conservées de ce virus. L'invention traite aussi de virosomes qui peuvent être formulés, de manière avantageuse, comme vaccins permettant d'induire des réponses des lymphocytes T cytotoxiques et des anticorps à forte neutralisation, ainsi qu'une protection contre les sources pathogènes comme le virus des oreillons. En outre, l'invention a pour objet des vaccins comprenant de l'ADN de recombinaison dérivés de l'ADN codant des protéines internes et externes conservées, provenant du virus des oreillons.
PCT/EP1998/003050 1991-05-08 1998-05-22 Vaccin comprenant de l'adn a enveloppe du virus de la grippe WO1998052603A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU79153/98A AU7915398A (en) 1997-05-23 1998-05-22 An influenza enveloped dna vaccine
EP98929369A EP0988052A2 (fr) 1997-05-23 1998-05-22 Vaccin comprenant de l'adn a enveloppe du virus de la grippe
US10/269,501 US20030113347A1 (en) 1991-05-08 2002-10-10 Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97108390 1997-05-23
EP97108390.2 1997-05-23

Publications (2)

Publication Number Publication Date
WO1998052603A2 WO1998052603A2 (fr) 1998-11-26
WO1998052603A3 true WO1998052603A3 (fr) 1999-05-14

Family

ID=8226824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003050 WO1998052603A2 (fr) 1991-05-08 1998-05-22 Vaccin comprenant de l'adn a enveloppe du virus de la grippe

Country Status (3)

Country Link
EP (1) EP0988052A2 (fr)
AU (1) AU7915398A (fr)
WO (1) WO1998052603A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102407A1 (fr) * 2001-06-15 2002-12-27 Nordic Vaccine Technology A/S Vaccination therapeutique
BR0316402A (pt) * 2002-11-21 2006-02-21 Pevion Biotech Ltd vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
EP1676569A1 (fr) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilisation de virosomes
EP2471937A3 (fr) * 2005-11-24 2013-04-24 The Research Foundation for Microbial Diseases of Osaka University Vaccin polyvalent recombiné
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305229A1 (fr) * 1987-07-07 1989-03-01 Transgene S.A. Vecteur viral et ADN recombinant codant pour une ou des protéines de structure (HA, F et/ou NP), d'un morbillivirus.
WO1992019267A1 (fr) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Virosomes de la grippe reconstitues immunostimulants et immunopotentialisants et vaccins en contenant
WO1994025600A1 (fr) * 1993-04-30 1994-11-10 Smithkline Beecham Biologicals S.A. Antigenes recombines du virus ourlien et leur utilisation dans les vaccins
WO1995010632A1 (fr) * 1993-10-12 1995-04-20 Emory University Procede de selection de l'anti-paramyxovirus, et vaccin
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
WO1996040962A1 (fr) * 1995-06-07 1996-12-19 Megabios Corporation Complexes lipide cationique/adn pour ciblage genique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
EP0305229A1 (fr) * 1987-07-07 1989-03-01 Transgene S.A. Vecteur viral et ADN recombinant codant pour une ou des protéines de structure (HA, F et/ou NP), d'un morbillivirus.
WO1992019267A1 (fr) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Virosomes de la grippe reconstitues immunostimulants et immunopotentialisants et vaccins en contenant
WO1994025600A1 (fr) * 1993-04-30 1994-11-10 Smithkline Beecham Biologicals S.A. Antigenes recombines du virus ourlien et leur utilisation dans les vaccins
WO1995010632A1 (fr) * 1993-10-12 1995-04-20 Emory University Procede de selection de l'anti-paramyxovirus, et vaccin
WO1996040962A1 (fr) * 1995-06-07 1996-12-19 Megabios Corporation Complexes lipide cationique/adn pour ciblage genique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATO T ET AL: "SYNTHETIC CATIONIC AMPHIPHILE FOR LIPOSOME-MEDIATED DNA TRANSFECTION WITH LESS CYTOTOCICITY", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), vol. 19, no. 6, 1 June 1996 (1996-06-01), pages 860 - 863, XP000594656 *
STERNBERG B: "MORPHOLOGY OF CATIONIC LIPOSOME/DNA COMPLEXES IN RELATION TO THEIR CHEMICAL COMPOSITION", JOURNAL OF LIPOSOME RESEARCH, vol. 6, no. 3, August 1996 (1996-08-01), pages 515 - 533, XP002048618 *
WASAN E K ET AL: "PLASMID DNA IS PROTECTED AGAINST ULTRASONIC CAVITATION-INDUCED DAMAGE WHEN COMPLEXED TO CATIONIC LIPOSOMES", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 4, 1 April 1996 (1996-04-01), pages 427 - 433, XP000558752 *
WILD ET AL.: "CONSTRUCTION OF VACCINIA VIRUS RECOMBINANTS EXPRESSING SEVERAL MEASLES VIRUS PROTEINS AND ANALYSIS OF THEIR EFFICACY IN VACCINATION OF MICE", JOURNAL OF GENERAL VIROLOGY, vol. 173, no. 2, February 1992 (1992-02-01), pages 359 - 367, XP002097543 *

Also Published As

Publication number Publication date
AU7915398A (en) 1998-12-11
WO1998052603A2 (fr) 1998-11-26
EP0988052A2 (fr) 2000-03-29

Similar Documents

Publication Publication Date Title
WO2001060402A3 (fr) Vaccin antigrippal a base de proteosomes
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
ES2129386T1 (es) Vacuna contra influenza.
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
BR9406007A (pt) Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2004080403A3 (fr) Vaccin contre le virus de la grippe
WO2002009645A3 (fr) Vaccin moleculaire permettant de relier une proteine a diffusion intracellulaire a un antigene
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
WO1998052603A3 (fr) Vaccin comprenant de l'adn a enveloppe du virus de la grippe
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
FR2828405B1 (fr) Vaccin anti-coronavirus
KR900701291A (ko) 혈호균속 인플루엔자용 백신과 진단검사법
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DK1499349T3 (da) Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
WO2003022880A3 (fr) Proteines d'enveloppe de synthese du virus de l'hepatite c (vhc) et leurs utilisations pour la vaccination
ZA941853B (en) Stimulation of immune response by viral protein
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
WO2001049712A3 (fr) Vaccin destine a la prevention et/ou la prophylaxie de l'anemie infectieuse du saumon chez des poissons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09264551

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998929369

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998549980

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998929369

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1998929369

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998929369

Country of ref document: EP